Item 1.01 Entry Into a Material Definitive Agreement.

On January 26, 2023, as a condition to and simultaneous with the closing of the equity issuance contemplated by the Share Purchase Agreement (the "Share Purchase Agreement"), dated December 13, 2022, by and between Wave Life Sciences Ltd. (including its subsidiaries, the "Company" or "Wave") and Glaxo Group Limited ("GGL"), the Company entered into an Investor Agreement with GGL (the "Investor Agreement"). A description of the terms and conditions of the Investor Agreement that are material to the Company is set forth in the Current Report on Form 8-K filed by the Company on December 13, 2022 under the heading "Equity Investment" in Item 1.01 of such Current Report on Form 8-K, which description is incorporated herein by reference.

Item 8.01 Other Events.

On January 26, 2023, Wave closed on the issuance and sale of 10,683,761 ordinary shares to GGL and received aggregate cash proceeds of approximately $50.0 million in respect of the sale. The sale was made pursuant to the terms of the Share Purchase Agreement, the terms of which were previously disclosed by Wave in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2022.

As a result of the closing under the Share Purchase Agreement, the Collaboration and License Agreement, dated December 13, 2022, by and among Wave Life Sciences USA, Inc., Wave Life Sciences UK Limited and GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK") (the "Collaboration Agreement"), became effective on January 27, 2023. Accordingly, GSK is now required to pay Wave the upfront cash payment of $120.0 million and the first installment of research support funding in respect of target validation activities under the collaboration.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses